Session (CTI)

PURPOSE: While HEOR has broad applications across the healthcare industry, its role in life science investing has historically been limited. In recent years, there has been a growing trend of HEOR professionals collaborating with investment banks and venture capitalists (VC). Why are banks and VCs thinking about health economics? Can health economics inform investment decisions? Can HEOR methods and thinking improve return on investment for life science investors? This panel convenes a group of health economists collaborating with various financial institutions to explore these questions. Each panelist will discuss the potential applications of HEOR in life science investing and outline opportunities and challenges for collaborations among the different sectors. DESCRIPTION: Meng Li will introduce the panelists, and highlight the growing synergy between HEOR and finance. She will briefly discuss how different types of HEOR research can be used to inform investment decisions. The discussion will then feature insights from three panelists:Will Canestaro will offer a perspective of a seed-stage healthcare and biotech investor, sharing how HEOR methods are being used to inform investment decisions and how he has built programs to incorporate HEOR methods in decision-making. Richard Xie will focus on the applications of HEOR methods to inform investment in later-stage companies (e.g., phase 2 or 3), and support policy and communication initiatives of investors. Melanie Whittington will discuss the differences in the modeling approach, timing, and frequency of updates between the financial sector and the value assessment sector. Each panelist will share how HEOR is being applied in their current positions and discuss opportunities for additional synergies between the health economic and financial sectors. The workshop will end with an interactive Q&A, allowing the audience to directly engage with panelists to discuss the emerging intersection between HEOR and investing.